Recent advances in nanomaterial-enhanced enzyme-linked immunosorbent assays

L, Gao; Yang, Qianfan; Wu, Peng; Li, Feng

doi:10.1039/d0an00597e

Cited by 46 publications

(34 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the simple operation and cost efficiency, it suffers from low sensitivity to biological samples [312]. Using nanomaterials as carriers of enzymes is an effective strategy, since they are able to increase the sensitivity of detecting markers of different types of cancer from 2 to 13 fold [313][314][315][316]. For this purpose, gold nanoparticles carrying the enzyme horseradish peroxidase are the most often used, but reports of employment of other nanomaterials and enzymes can also be found in the literature [312][313][314].…”

Section: Detection Of Cancer Biomarkersmentioning

confidence: 99%

Designing of Nanomaterials-Based Enzymatic Biosensors: Synthesis, Properties, and Applications

et al. 2021

View full text Add to dashboard Cite

Among the many biological entities employed in the development of biosensors, enzymes have attracted the most attention. Nanotechnology has been fostering excellent prospects in the development of enzymatic biosensors, since enzyme immobilization onto conductive nanostructures can improve characteristics that are crucial in biosensor transduction, such as surface-to-volume ratio, signal response, selectivity, sensitivity, conductivity, and biocatalytic activity, among others. These and other advantages of nanomaterial-based enzymatic biosensors are discussed in this work via the compilation of several reports on their applications in different industrial segments. To provide detailed insights into the state of the art of this technology, all the relevant concepts around the topic are discussed, including the properties of enzymes, the mechanisms involved in their immobilization, and the application of different enzyme-derived biosensors and nanomaterials. Finally, there is a discussion around the pressing challenges in this technology, which will be useful for guiding the development of future research in the area.

show abstract

Section: Detection Of Cancer Biomarkersmentioning

confidence: 99%

Designing of Nanomaterials-Based Enzymatic Biosensors: Synthesis, Properties, and Applications

et al. 2021

View full text Add to dashboard Cite

show abstract

“…It is highly possible that uninfected individuals can be inadvertently exposed to pathogens and become infected while waiting for test results, making conventional ELISAs not suitable for POC detection. Numerous attempts have been made to improve the original ELISA, which include the incorporation of nanomaterials as alternatives to enzymes and nanozymes (e.g., Fe 3 O 4 magnetic nanoparticles, and carbon dots) [35] or substrates (e.g., gold nanoparticles, [36] silver nanoparticles, and luminescent nanoparticles). Enzymefree amplifiers that provide more noticeable color changes than the commonly used colorimetric substrates (i.e., hybridization chain reaction, molecular beacons) are an alternative option (Figure 3a).…”

Section: Enzyme-linked Immunosorbent Assaymentioning

confidence: 99%

Advanced Nanomaterials for Preparedness Against (Re‐)Emerging Viral Diseases

et al. 2021

View full text Add to dashboard Cite

While the coronavirus disease (COVID‐19) accounts for the current global pandemic, the emergence of other unknown pathogens, named “Disease X,” remains a serious concern in the future. Emerging or re‐emerging pathogens continue to pose significant challenges to global public health. In response, the scientific community has been urged to create advanced platform technologies to meet the ever‐increasing needs presented by these devastating diseases with pandemic potential. This review aims to bring new insights to allow for the application of advanced nanomaterials in future diagnostics, vaccines, and antiviral therapies, thereby addressing the challenges associated with the current preparedness strategies in clinical settings against viruses. The application of nanomaterials has advanced medicine and provided cutting‐edge solutions for unmet needs. Herein, an overview of the currently available nanotechnologies is presented, highlighting the significant features that enable them to control infectious diseases, and identifying the challenges that remain to be addressed for the commercial production of nano‐based products is presented. Finally, to conclude, the development of a nanomaterial‐based system using a “One Health” approach is suggested. This strategy would require a transdisciplinary collaboration and communication between all stakeholders throughout the entire process spanning across research and development, as well as the preclinical, clinical, and manufacturing phases.

show abstract

“…[2]. As a result, the term ELISA now refers to a wide range of micro-welled plate assays, some of which do not involve enzymatic reactions [3][4][5] and/or immune complex formation [6,7]. Since current research interest is dictated by the requirement of greater throughput and sensitivity alternatives, as well as cheaper, conventional immunoassays could gradually be replaced by abiotic ELISAs.…”

Section: Introductionmentioning

confidence: 99%

“…Since current research interest is dictated by the requirement of greater throughput and sensitivity alternatives, as well as cheaper, conventional immunoassays could gradually be replaced by abiotic ELISAs. In this context, several efforts have been already devoted to discovering new signal reporters to increase ELISA sensitivity [3] and to pinpoint capturing agents, i.e., mimetics [8], able to flank and/or supplant antibodies that generally are expensive and sensitive to environmental conditions. Looking at mimetic capturing agents, the literature has highlighted aptamers and molecularly imprinted polymers (MIPs) as the most promising ones to develop diagnostic "antibody-free" ELISA-like format assays, i.e., enzymelinked oligonucleotide assay (ELONA) [6,9], biomimetic enzyme-linked immunoassay (BELISA) [10][11][12][13][14][15][16][17][18][19], pseudo-ELISA [7,[20][21][22][23], or nanoparticle-based assay (MINA) [1,15,[24][25][26][27][28][29].…”

Section: Introductionmentioning

confidence: 99%

A biomimetic enzyme-linked immunosorbent assay (BELISA) for the analysis of gonadorelin by using molecularly imprinted polymer-coated microplates

et al. 2022

View full text Add to dashboard Cite

An original biomimetic enzyme-linked immunoassay (BELISA) to target the small peptide hormone gonadorelin is presented. This peptide has been recently listed among the substances banned in sports by the World Antidoping Agency (WADA) since its misuse by male athletes triggers testosterone increase. Hence, in response to this emerging issue in anti-doping controls, we proposed BELISA which involves the growth of a polynorepinephrine (PNE)–based molecularly imprinted polymer (MIP) directly on microwells. PNE, a polydopamine (PDA) analog, has recently displayed impressive performances when it was exploited for MIP preparation, giving even better results than PDA. Gonadorelin quantification was accomplished via a colorimetric indirect competitive bioassay involving the competition between biotinylated gonadorelin linked to the signal reporter and the unlabeled analyte. These compete for the same MIP binding sites resulting in an inverse correlation between gonadorelin concentration and the output color signal (λ = 450 nm). A detection limit of 277 pmol L−1 was achieved with very good reproducibility in standard solutions (avCV% = 4.07%) and in urine samples (avCV% = 5.24%). The selectivity of the assay resulted adequate for biological specimens and non-specific control peptides. In addition, the analytical figures of merit were successfully validated by mass spectrometry, the reference anti-doping benchtop platform for the analyte. BELISA was aimed to open real perspectives for PNE-based MIPs as alternatives to antibodies, especially when the target analyte is a poorly or non-immunogenic small molecule, such as gonadorelin. Graphical abstract

show abstract

Recent advances in nanomaterial-enhanced enzyme-linked immunosorbent assays

Abstract: This review highlights functional roles of nanomaterials for advancing conventional ELISA assays by serving as substrate-alternatives, enzyme-alternatives, or non-enzyme amplifiers.

Cited by 46 publications

References 114 publications

Designing of Nanomaterials-Based Enzymatic Biosensors: Synthesis, Properties, and Applications

Designing of Nanomaterials-Based Enzymatic Biosensors: Synthesis, Properties, and Applications

Advanced Nanomaterials for Preparedness Against (Re‐)Emerging Viral Diseases

A biomimetic enzyme-linked immunosorbent assay (BELISA) for the analysis of gonadorelin by using molecularly imprinted polymer-coated microplates

Contact Info

Product

Resources

About